# Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors

> **NCT07224568** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Seattle Children's Hospital** · enrollment: 21 (estimated)

## Conditions studied

- Solid Tumor (Excluding CNS)
- Hepatocellular Carcinoma
- Liver Cell Carcinoma
- Liposarcoma
- Yolk Sac Tumor
- Rhabdomyosarcoma

## Interventions

- **BIOLOGICAL:** SC-CAR.GPC3xIL15.21 CAR T cells

## Key facts

- **NCT ID:** NCT07224568
- **Lead sponsor:** Seattle Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2030-08
- **Final completion:** 2045-08
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2025-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07224568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07224568, "Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07224568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*